ArticleArthritis research & therapy2003
SLE - Rituximab in lupus.
Article in Arthritis research & therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Single mutation tunes IRF4 function and mediates B cell character to ameliorate murine lupus.iScience · 2025Article
- The initial presentation of systemic lupus erythematosis with aplastic anemia successfully treated with rituximab.Clinical rheumatology · 2012Review
- Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE.Autoimmune diseases · 2010Article
- Association of the BANK 1 R61H variant with systemic lupus erythematosus in Americans of European and African ancestry.The application of clinical genetics · 2009Article
- Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma.Rheumatology international · 2007Article
- A rare case of autoimmune haemolytic anaemia due to warm IgA autoantibodies with reticulocytopenia.Internal and emergency medicine · 2007Article
- Update on rituximab.Annals of the rheumatic diseases · 2005Review
- Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.Pediatric nephrology (Berlin, Germany) · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.